Alliance Pharma Share Discussion Threads

[cumnor] 20/4/2017 22:21

TW nothing to do with 21ml volume whatsoever. Something up?

[pugugly] 20/4/2017 21:51

If TW tipped maybe best to wait a few weeks until short term punters sell to skim a small profit = prices fall back and then stop losses triggered - then maybe possible to consider - Apparently a well managed company though debt moderately high but being worked down. But DYOR etc.

[craigy] 20/4/2017 16:36

21m traded??? A tad unusual

[craigy] 20/4/2017 15:37

10m traded???

[2vdm] 20/4/2017 13:21

Tipped by TW again, which some regards as the Kiss of Death

[al101uk] 30/3/2017 12:07

DVB99,

Thought the same thing, I think it's more the cash generation here that makes the level comfortable than the level itself.

Not a concern, but made me smile all the same.

[dvb99] 30/3/2017 11:59

this made me laugh -

"At the year-end, the adjusted net debt/EBITDA ratio was 2.8 times and comfortably below our banking covenant of 3.0 times."

COMFORTABLY - really??????????

[nw99] 30/3/2017 07:29

Good buy rec in today's Times BUY

[2vdm] 29/3/2017 14:39

I agree. I think this is a bit under the radar, but definitely a long term hold

[dozey3] 29/3/2017 13:29

Guess the market is underwhelmed because of debt, gearing at 2.8. However it has reduced by £3m since June with the £5m Sinclair payment to come, so provided we can continue to keep cash rolling in and debt decreasing it's a bargain below 50p IMO.

[al101uk] 29/3/2017 12:08

Looks good, would have liked a bit more clarification on the compensation from Sinclair, but management seem capable and gains elsewhere in the business appear to be compensating for the issues with Kelo-stretch. In effect the £5 million and the US rights to Flammacerium could be considered a bonus in excess of expectations.

Happy to hold and may be tempted to add on any weakness in the new tax year.

[nw99] 29/3/2017 11:56

Doubled up here

[2vdm] 29/3/2017 07:46

Excellent set of results and well done to the BOD. share price more than justified imo. Hopefully onwards and upwards.

[nw99] 29/3/2017 07:25

Sales and profits have doubled nice

[al101uk] 21/3/2017 12:20

From April 2016:

"Since completion of the acquisition in mid-December 2015, sales of Kelo-stretchTM, which had been identified as a key growth brand, have been lower than anticipated despite extensive promotional activities by A. Menarini Asia-Pacific Pte. Ltd., our key partner in South East Asia. Despite this, other Sinclair brands they distribute for us are performing well. The relationship with Menarini remains strong and other opportunities are being positively explored. The 2016 impact of the Kelo-stretch shortfall is estimated at a possible reduction of £1.2m at the operating profit level. Notwithstanding this, trading to date for the Sinclair Healthcare Products in aggregate has remained in line with management's expectations."

"The fair value of intangible assets recognised on business combination comprise the following product related intangibles: Aloclair, Atopiclair, Flamma franchise, Kelo-cote, Kelo-stretch, Other Dermatology Products and Other Specialist Hospital Products."

Worth keeping an eye on amortisation of intangible assets at results.

[nw99] 21/3/2017 07:11

Great news £5m better off this am

[nw99] 13/3/2017 09:22

Buying ahead of results

[2vdm] 01/3/2017 08:00

I agree with your views re longer term prospects but suspect that as it grows it may become a target for a larger fish.

[norbert colon] 28/2/2017 09:50

I have added on the recent weakness. Held since early 2011 and like the long term prospects and relative stability of the business. I intend for APH to remain in my portfolio for 10yrs +

[pugugly] 27/2/2017 16:53

Moderate volume and continuing fall in share price 4 day faller down 9.55% - No news. Could an II be unloading ? Looks as though going nowhere at the moment or could it be those who bought in on the Hardman reseach having stop losses triggered -
Any other thoughts / knowledge ?

[norbert colon] 24/1/2017 18:11

I should have clarified that earnings will increase post 2017 as the Sinclair IS costs will have then fully passed though the business. It's a great solid business with strong mgt and one to tuck away and forget.

[2vdm] 24/1/2017 17:36

Thanks Norbert. I found a bit in their RNS about primarily focusing on developing on what they've acquired so far during 2017, but useful to have some projections.Hopefully we will get more news spring/summer. I haven't been able to find a similar type of business to see if the PE is good or not, but my instinct is that this is undervalued at 49p.

[norbert colon] 24/1/2017 14:30

Rev of £98.2m and EPS of 4p for 2017 is current forecast but may now be updated. Growth from Sinclair only really kicks in from 2017 onwards.